Thursday 16 October, 2025
Objectives: To characterise the pharmacokinetics of the antimalarial amodiaquine (AQ) and its active metabolite desethylamodiaquine (DEAQ) to a) test whether…
Read morePoster: Drug/Disease modeling - Infection
Semi-mechanistic multiple-analyte pharmacokinetic model for a THIOMAB antibiotic conjugate against Staphylococcus aureus in mouse, rat and monkey
Thursday 16 October, 2025
Objectives: Staphyloccocus aureus (S. aureus) is a bacterial pathogen causing life threatening diseases such as bacteremia and bone infections. We have…
Read morePK/PD Modeling of Tuberculosis for Identification of Biomarkers Associated with Treatment Duration
Thursday 16 October, 2025
Objectives: Treatment duration shortening is a major priority for current Tuberculosis (TB) drug development, yet recent clinical trials have failed to…
Read morePharmacokinetic-Pharmacodynamic modeling of miltefosine in Leishmania donovani infected Golden Syrian Hamsters
Thursday 16 October, 2025
Objectives: The knowledge about the exposure-effect relationship of miltefosine (MF) is limited, which is imperative for understanding the risk factors associated…
Read moreJoint modeling of plasma and fecal moxifloxacin pharmacokinetics in healthy volunteers
Thursday 16 October, 2025
Objectives: Antibiotic administration leads to fecal microbiota disruption with emergence of antimicrobial resistance [1]. Animal data suggest that emergence of…
Read morePopulation Pharmacokinetics of the Novel Antimalarial OZ439
Thursday 16 October, 2025
Objectives: OZ439 is a novel synthetic anti-malarial compound related to the artemisinin, but with a longer elimination half-life, which is being…
Read morePopulation pharmacokinetics of meropenem during intermittent and continuous infusion in healthy volunteers
Thursday 16 October, 2025
Objectives: Meropenem is a broad-spectrum antibacterial agent that has been used for decades. In an era of increasing emergence of drug…
Read moreDevelopment of a novel multi-compartment granuloma model to predict local drug distribution and its impact on pharmacodynamics and disease progression in tuberculosis.
Thursday 16 October, 2025
Objectives: One of the hallmarks of pulmonary tuberculosis (TB) is the formation of granulomas, heterogeneous lesions composed of macrophage and…
Read morePopulation Pharmacokinetic Modeling of Ciprofloxacin Free Lung Concentrations in Healthy and Pseudomonas aeruginosa Biofilm Infected Wistar Rats
Thursday 16 October, 2025
Objectives: Biofilm is an important virulence factor that allows bacteria to resist host responses and antimicrobials [1]. Although several pharmacodynamic…
Read morePopulation pharmacokinetics of linezolid in critically ill patients and treatment probability of target attainment
Thursday 16 October, 2025
Objectives: The main goal of this study was to build a population PK model for the antibiotic linezolid (LZD) in…
Read more